Therapeutic maintenance effect of finasteride 1 mg every other month regimen in androgenetic alopecia and study on the difference in response to finasteride treatment: A prospective cohort study
Authors:
- 31 January 2024
- journal article
- research article
- Published by Wiley in The Journal of Dermatology
- Vol. 51 (4) , 552-557
Abstract
Finasteride is commonly used for androgenetic alopecia (AGA) treatment. The aim of this study was to assess the therapeutic maintenance effect of a finasteride every other month (EOM) regimen and analyze clinical and laboratory differences in patients with AGA according to their treatment response. One hundred males with AGA who received finasteride 1 mg daily treatment for a year were enrolled in the study. At 1 year follow‐up, treatment responses of patients who completed the visit schedule were assessed using five scales. The patients were assigned to good or bad response groups according to their assessment. Further, they were randomly divided into two groups (daily vs. EOM) and treated with finasteride (1 mg) for 1 more year. At 2 years follow‐up, treatment efficacy was assessed. At 1‐year follow‐up, 36 patients completed the schedule, including eight and three patients in the good and bad response groups, respectively. At the 2‐year follow‐up, 23 patients completed the schedule, with nine in the daily group and 14 in the EOM group. Changes in global photographic assessment in the second year were 1.33 and 1.29 for the daily and EOM groups, respectively. The daily group showed an elevated hair density and lower concentration of dihydrotestosterone (DHT) and the DHT to testosterone ratio (DHT/T). However, the EOM group showed decreased hair density and elevated DHT and DHT/T. Following treatment response assessment after 1 year of treatment, the good response group showed early onset which was associated with maternal AGA. Analysis of serum androgen hormone magnitude of DHT reduction was much greater (54.4% vs. 44.4%). DHT/T was higher in the bad response group (1.98 vs. 2.33). We concluded that the finasteride EOM regimen showed similar maintenance effects to the daily regimen.Keywords
This publication has 12 references indexed in Scilit:
- Medication-Related Burden among Patients with Chronic Disease Conditions: Perspectives of Patients Attending Non-Communicable Disease Clinics in a Primary Healthcare Setting in QatarPharmacy, 2018
- Androgens and androgen receptor action in skin and hair folliclesMolecular and Cellular Endocrinology, 2018
- Intracrine androgen biosynthesis, metabolism and action revisitedMolecular and Cellular Endocrinology, 2018
- Characteristics of Androgenetic Alopecia in AsianAnnals of Dermatology, 2012
- Use of Finasteride in the Treatment of Men With Androgenetic Alopecia (Male Pattern Hair Loss)Journal of Investigative Dermatology Symposium Proceedings, 2003
- Clinical dose ranging studies with finasteride, a type 2 5α-reductase inhibitor, in men with male pattern hair lossJournal of the American Academy of Dermatology, 1999
- Finasteride in the treatment of men with androgenetic alopeciaJournal of the American Academy of Dermatology, 1998
- Clinical Pharmacokinetics and Pharmacodynamics of FinasterideClinical Pharmacokinetics, 1996
- Steroid 5α-Reductase Deficiency in Man: An Inherited Form of Male PseudohermaphroditismScience, 1974
- Male hormone stimulation is prerequisite and an incitant in common baldnessJournal of Anatomy, 1942